Aromha Inc

Aromha Inc develops and commercializes the Aromha Brain Health Test, a non-invasive, at-home olfactory screening tool designed for early detection of cognitive decline and neurodegenerative diseases, particularly Alzheimer's Disease and related dementias. The test was developed by Dr. Mark Albers, an Assistant Professor of Neurology at Harvard Medical School and Massachusetts General Hospital, and leverages research showing that olfactory dysfunction correlates with Alzheimer's Disease pathology years before symptom onset. The assessment consists of a simple smell test coupled with a user-friendly web-based application that delivers personalized insights and recommendations. The company targets individuals concerned about memory loss, cognitive decline, or family history of dementia, positioning early detection as enabling informed clinical decision-making, lifestyle interventions (exercise, sleep, diet), participation in early-stage clinical trials, and proactive life planning. The test is marketed directly to consumers and has received significant media coverage from news outlets including NBC Boston, WCVB, and NewsNation. The company is based in the Washington, DC metropolitan area and focuses on democratizing access to cognitive health screening outside traditional clinical settings.